

<b>REPORT TO:</b>	<b>HEALTH AND WELLBEING BOARD</b> 18th November 2022
<b>SUBJECT:</b>	Pharmaceutical Needs Assessment
<b>BOARD SPONSOR:</b>	Rachel Flowers, Director of Public Health, Croydon Council
<b>PUBLIC/EXEMPT:</b>	

**SUMMARY OF REPORT:**

- The 2022 Croydon Pharmaceutical Needs Assessment has been completed.
- The Board is requested to sign off the 2022 Croydon Pharmaceutical Needs Assessment for immediate publication.

**BOARD PRIORITY/POLICY CONTEXT:**

Every Health and Wellbeing Board (HWB) in England has a statutory responsibility to publish and keep up to date a statement of the needs for pharmaceutical services of the population in its area, referred to as a Pharmaceutical Needs Assessment (PNA).

The purpose of the PNA is to plan for the commissioning of pharmaceutical services and to support the decision-making process in relation to new applications of change of premises of pharmacies.

**FINANCIAL IMPACT:**

- No financial impact for Health and Wellbeing Board partners.

**RECOMMENDATIONS:**

- To sign off the 2022 Croydon Pharmaceutical Needs Assessment.

## **1. EXECUTIVE SUMMARY**

- 1.1 This paper provides a summary of the process to produce and publish the 2022 PNA.
- 1.2 Croydon Council commissioned PHAST CIC to develop the 2022 PNA on behalf of the HWB.
- 1.3 As part of the process, two surveys were conducted between May and July to gain views from Pharmacy Contractors and residents. A 60-days consultation took place from 31 August to 29 October 2022.
- 1.4 The final report will be published in November 2022, following approval from the HWB.

## **2. DETAIL**

### **PNA Development and Publication**

- 2.1 In January 2022, Croydon Council commissioned PHAST CIC to produce the 2022 PNA on behalf of the HWB.
- 2.2 A steering group was established with representatives from the Croydon Council, South West London Integrated Care Board, Local Pharmaceutical Committee, Local Medical Committee, and Healthwatch Croydon. The function of the steering group is to oversee the production of the 2022 PNA for the London Borough of Croydon, reporting progress to the HWB.
- 2.3 As part of the PNA process, two surveys were conducted between May and July: (i) the Croydon Pharmacy Contractor survey was conducted to inform the PNA (80% response rate, or 58 of 73 pharmacies in Croydon.); and (ii) the Public PNA survey to gain views from residents about pharmacy services in Croydon (327 participants completed the survey, and more than 99% were Croydon residents).
- 2.4 The final phase consisted in a 60-days public consultation that took place from 31 August to 29 October 2022.
- 2.5 The final PNA is now ready for publication, following approval from the HWB.

## **3. CONSULTATION**

- 3.1 A 60-days public consultation on the draft PNA is currently underway (from 31 August to 29 October. The draft consultation can be found here: <https://www.getinvolved.croydon.gov.uk/pharmacy>)

## **4. SERVICE INTEGRATION**

- 4.1 PNAs provide a common structured framework within which commissioners and strategic planners can make decisions about pharmaceutical needs in a local area.

They facilitate discussions between NHS England, local commissioners from the local authority and CCG, and local pharmacists around addressing local pharmaceutical needs, and provide a common framework for assessing activity and provision that should be in place to address these needs.

## **5. FINANCIAL AND RISK ASSESSMENT CONSIDERATIONS**

5.1 There are no financial implications or risks that the board needs to consider. The PNA supports NHS England to make decisions about market entry. It has no direct cost implications to the Council or CCG.

5.2 The funding to undertake and develop the refreshed 2022 PNA has been identified as part of the public health ring-fenced grant.

Approved by: Nish Popat - Interim Head of Corporate Finance, Croydon Clinical Commissioning Group

## **6. LEGAL CONSIDERATIONS**

6.1 There is a statutory responsibility to produce a PNA. The Health and Wellbeing Board's review of the refreshed PNA will need to be supported by full legal clearance.

6.2 The Health and Social Care Act 2012 established Health and Wellbeing Boards and transferred to them (from the NHS Act 2006) the responsibility to publish and keep up to date a statement of the needs for pharmaceutical services of the population in its area, with effect from 1 April 2013. The requirements on how to develop and update PNAs are set out in Regulations 3-9 Schedule 1 of the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013.

6.3 The 2012 Act also amended the Local Government and Public Involvement in Health Act 2007 to introduce duties and powers for Health and Wellbeing Boards in relation to Joint Strategic Needs Assessments (JSNAs). The preparation and consultation on the Pharmaceutical Needs Assessment should take account of the Joint Strategic Needs Assessment (and other relevant local strategies in order to prevent duplication of work and multiple consultations with health groups, patients and the public). The development of Pharmaceutical Needs Assessments is a separate duty to that of developing Joint Strategic Needs Assessments. As a separate statutory requirement, Pharmaceutical Needs Assessments cannot be subsumed as part of these other documents but can be annexed to them.

6.4 The Health and Social Care Act 2012 also transferred responsibility for using PNAs as the basis for determining market entry to a pharmaceutical list from PCTs to NHS England.

Approved by Sandra Herbert, Head of Litigation and Corporate Law on behalf of the Director of Legal Services and Monitoring Officer

## **7. HUMAN RESOURCES IMPACT**

- 7.1 There are no direct human resource impacts arising from the content of this report for Croydon Council employees or staff.
- 7.2 Approved by: Gillian Bevan, Head of HR, Resources and Assistant Chief Executives on behalf of the Chief People Officer.

## **8. EQUALITIES IMPACT**

- 8.1 The purpose of any needs assessment, including the PNA, is to look at current and predicted future population needs for service provision or support. The PNA will identify the need for access to pharmaceutical services so that NHS England can approve or reject applications for additions to the pharmaceutical list. The PNA will also identify the need for locally commissioned services that local authority and CCG commissioners can respond to using relevant commissioning budgets.
- 8.2 As part of the PNA process, an “Equality Impact Assessment” (EIA) has been completed and signed off.
- 8.3 There are no negative impacts regarding groups with protected characteristics identified in the EQIA.

Approved By; Denise McCausland – Equality Programme Manager

---

**CONTACT OFFICER:** Director of Public Health, Rachel Flowers  
Rachel.flowers@croydon.gov.uk